Completed OBSERVATIONAL NCT00579670

Treatment of Schizophrenic Patients With Ziprasidone (TRITON)

Treatment of Schizophrenic Patients With Geodon; Capsules/Oral Suspension/Solution for Injection (Ziprasidone)

Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Interventions Ziprasidone

Updated 10 times since 2017 Last updated: Feb 18, 2021 Started: Oct 31, 2007 Primary completion: Apr 30, 2009 Completion: Apr 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Schizophrenia, this trial is completed. The trial is conducted by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. and has accumulated 10 data snapshots since 2007. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Status Flow

Change History

10 versions recorded

Sep 2025 — Present [monthly]

Completed
Sep 2024 — Sep 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Dec 2021 — Jul 2024 [monthly]

Completed
Apr 2021 — Dec 2021 [monthly]

Completed

▶ Show 5 earlier versions

Jan 2021 — Apr 2021 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed
Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None
Feb 2017 — Apr 2018 [monthly]

Completed NA
Jan 2017 — Feb 2017 [monthly]

Completed NA

First recorded

Oct 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Athens, Greece , Chaïdári, Greece , Corfu, Greece , Crete, Greece , Giannitsá, Greece , Haidari, Greece , Kalamata, Greece , Katerini, Greece , Kozani, Greece , Lamia, Greece and 4 more locations